Skip to search formSkip to main contentSkip to account menu

AEG 35156

Known as: AEG35156, GEM 640, GEM640 
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Objectives:AEG35156 is an antisense oligonucleotide (ASO) that targets the X-linked inhibitor of apoptosis mRNA. Preclinical… 
2012
2012
Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
4105 Background: XIAP inhibits caspases which are proteases responsible for apoptotic cell death. It is highly expressed in HCC… 
2010
2010
Phase I portion of the phase I-II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
e14519 Background: The X-linked Inhibitor of Apoptosis (XIAP) inhibits caspases 3, 7 and 9 which are proteases responsible for… 
2009
2009
Apoptosis and cancer : mutations within caspase genes
1 Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada; 2 National Training Program in Allergy and Asthma… 
2008
2008
Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.
XIAP, a potent cellular inhibitor of caspases 3 and 9, is highly expressed in various malignant cells including AML cells and… 
2008
2008
Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML
XIAP (X-linked Inhibitor of Apoptosis protein) is an inhibitor of caspases 3 and 9 that is over-expressed in AML and may… 
2008
2008
X-linked inhibitor of apoptosis (XIAP) in colorectal cancer models
X-linked inhibitor of apoptosis (XIAP) is the most potent endogenous caspase inhibitor, preventing cell death via the caspase-9… 
2007
2007
Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.
C163 The X-linked inhibitor of apoptosis protein (XIAP) is a potent anti-apoptotic protein and is widely up-regulated in a… 
2006
2006
A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours
Background: The X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein. AEG35156 is a 2nd generation antisense… 
2006
2006
AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients
Proc Amer Assoc Cancer Res, Volume 47, 2006 4862 X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)